List view / Grid view
20 April 2015 | By Victoria White
TD2 and Navigating Cancer are teaming up to improve patient engagement in trials and bring patient-reported outcomes to the clinical trials process...
17 April 2015 | By Victoria White
MedImmune has entered into a collaboration with Immunocore to conduct immuno-oncology combination trials in metastic melanoma...
7 April 2015 | By Victoria White
Breakthrough Therapy designation has been granted for rucaparib as treatment of advanced ovarian cancer in patients with BRCA-mutated tumours...
18 March 2015 | By Victoria White
Novartis announce that the EU has approved Jakavi ® for the treatment of adult patients with polycythemia vera (PV)...
18 February 2015 | By GlobalData
The Chinese treatment market for colorectal cancer will expand almost fourfold in value from an estimated $259 million in 2013 to $1.05 billion by 2023, at an impressive Compound Annual Growth Rate of 15.1%, according to research and consulting firm GlobalData...
5 February 2015 | By Eli Lilly and Company
New funding builds on a longstanding partnership to help Kenyans receive quality care...
30 January 2015 | By AstraZeneca and The University of Texas MD Anderson Cancer Center
AstraZeneca and The University of Texas MD Anderson Cancer Center announced a multi-year, strategic research collaboration to conduct multiple, parallel clinical and clinically-related studies in ovarian and other gynecologic cancers with the aim of improving patient outcomes...
30 January 2015 | By GBI Research
The Asia-Pacific therapeutics market for Ovarian Cancer will undergo a modest rise in value, from $294.3 million in 2013 to $417.6 million by 2020, at a Compound Annual Growth Rate of 5.1%, says business intelligence provider GBI Research...
12 January 2015 | By Bristol-Myers Squibb Company
Seattle Genetics, Inc. and Bristol-Myers Squibb Company announced that the companies have entered into a clinical trial collaboration agreement to evaluate the investigational combination of Seattle Genetics’ antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) and Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in two planned Phase 1/2 clinical trials...
19 December 2014 | By Merck
Acquisition expands Merck’s oncology portfolio with novel oral BET inhibitor, OTX015...
5 December 2014 | By Evgen Pharma
Evgen Pharma plc, a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces its intention to join the AIM market of the London Stock Exchange by way of a Placing to raise up to £20 million...
10 November 2014 | By Bristol-Myers Squibb
Study results from investigational agents Opdivo (nivolumab), elotuzumab, and ulocuplumab, as well as Sprycel (dasatinib), will be highlighted...
5 November 2014 | By The Institute of Cancer Research, London
A pioneering cancer drug set to become the first to be approved specifically for inherited cancers could also be used much more widely to treat prostate cancer, a world-leading expert has said...
4 November 2014 | By KMR Group
KMR Group, a leader in analyzing R&D performance data for the biopharmaceutical industry, has recently assessed the duration of oncology trials...
14 October 2014 | By New Oncology
New Oncology announced that it has entered into a collaboration agreement with Gustave Roussy Cancer Campus, Paris...
